STEPHEN DAVIS
CIK 1131146 · CEO · last filed 2024-08-20
STEPHEN DAVIS is a CEO who has filed 109 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for ACAD, was dated Aug 20, 2024. Across all open-market trades the lifetime net is −$33.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.96M
8
109
-$33.35M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACAD | CEO | 186,555 | $21.09 | $3.93M | -$33.20M | 40 | 2024-08-20 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Director | 136,854 | $0.07 | $10.2K | $0 | 12 | 2023-01-05 |
| HRTX | Director | 52,032 | $0.40 | $20.8K | $0 | 10 | 2022-12-20 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | — | — | — | $0 | 5 | 2015-06-23 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | Director | 9,308 | — | — | $0 | 2 | 2014-03-04 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | EVP & COO | 0 | — | — | -$148.9K | 22 | 2012-06-20 |
| HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted | Director | 95,891 | — | — | $0 | 3 | 2011-02-22 |
| NEUROGEN CORP (NRGN) Delisted | President, CEO | — | — | — | $0 | 4 | 2008-07-29 |
Recent Filings
109 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-20 | ACAD | Mixed | +30,368 | -$485.1K | EDGAR |
| 2024-05-03 | ACAD | Mixed | +10,964 | -$193.6K | EDGAR |
| 2024-04-09 | ACAD | Mixed | +25,425 | -$474.9K | EDGAR |
| 2024-03-27 | ACAD | Mixed | +16,952 | -$317.1K | EDGAR |
| 2024-02-27 | ACAD | Mixed | +5,369 | -$137.6K | EDGAR |
| 2024-01-09 | ACAD | Mixed | +5,796 | -$111.8K | EDGAR |
| 2023-10-06 | ACAD | Mixed | +52,436 | -$1.13M | EDGAR |
| 2023-07-18 | ACAD | Mixed | — | -$927.4K | EDGAR |
| 2023-07-13 | ACAD | Sell (S) | −71,602 | -$1.79M | EDGAR |
| 2023-05-03 | ACAD | Grant (A) | — | $0 | EDGAR |